Investor Center

Press Releases

Press Releases

March 16, 2020
CAMBRIDGE, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced key leadership appointments, including the promotion of Manmohan Singh, Ph.D., from vice president to
February 11, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 11, 2020-- Beam Therapeutics Inc. (Nasdaq:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the closing of its initial public offering of 12,176,471 shares of common stock, including the exercise in
February 5, 2020
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the pricing of its initial public offering of 10,588,236 shares of common stock at a public offering price